FDA Backs Novartis MS Pill Mayzent With Broad Label

 
• By Kevin Grogan
  
Wall
Mayzent approval is a breakthrough for SPMS • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip